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Objective: Symptoms of salivary gland dysfunction frequently develop after radioactive
iodine (RAI) therapy, but have generally not been correlated with assessment of salivary
gland functioning. The aim of this study was to determine whether there was a correlation
between salivary symptoms and salivary functioning as assessed by salivary scan
parameters.
Methods: This was a non-randomized observational study. Fifteen patients receiving
RAI therapy for differentiated thyroid cancer completed a questionnaire assessing their
salivary and nasal symptoms prior to their therapy and 3 and 12months after their
therapy. Salivary gland scanning using technetium-99m pertechnetate was performed
at the same time points. In addition, protective measures used at the time of radioiodine
administration, such as use of fluids and sour candy, were also documented. Measures
of salivary gland accumulation and secretion were correlated with scores of salivary and
nasal symptomatology and any effects of protective measures were assessed.
Results: The mean number of salivary, nasal, and total symptoms at 3months increased
significantly over the number of symptoms at baseline by 3.7, 2.7, and 6.3 symp-
toms, respectively (p values 0.001, 0.0046, and <0.001, respectively). The mean
increases in the number of salivary, nasal, and total symptoms at 12months were
non-significant at 1.3, 1.3, and 2.5 symptoms, respectively. The mean right parotid
gland accumulation and secretion of radioisotope declined significantly at 3months,
compared with baseline. The changes in left parotid and right and left submandibular
function were non-significant. There was no association between the increase in salivary,
nasal, or total symptoms and the change in scintigraphy measures. However, the
increases in nasal and total symptoms were significantly greater in those with co-existent
Hashimoto’s disease, compared with those without this condition (p values 0.01 and
0.04, respectively). Nasal symptoms decreased (p value 0.04) and total symptoms
trended to decrease (p value 0.08) in those who used sour candies, compared with
those who did not. Increasing body mass index was significantly associated with
increasing nasal symptoms (p value 0.05). Greater decline in salivary parameters at
3months compared with baseline was generally associated with heavier body weight,
decreased thyroid cancer stage, absence of Hashimoto’s thyroiditis, and pre-menopausal
status.
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Conclusion: Salivary and nasal symptoms increased and salivary scintigraphy param-
eters decreased after radioiodine therapy. However, the increased symptoms did not
correlate with decrements in salivary gland accumulation or secretion. Moreover, the
variables associated with symptoms and changes in salivary scan parameters differed.
Therefore, a better understanding of the relationship between salivary gland symptoms
and functioning is needed. Factors affecting susceptibility to salivary and nasal damage
after radioiodine therapy need to be better elucidated, so that modifiable factors can be
identified.
Keywords: salivary symptoms, salivary dysfunction, salivary scintigraphy, nasal symptoms, radioiodine therapy
Introduction
Administered radioactive iodine (RAI) is actively transported
via the sodium iodide symporter and concentrated primarily by
benign andmalignant thyroid cells (1). Despite the proven efficacy
of RAI in the treatment of thyroid cancer, there are several serious
side effects associated with its use (2). These side effects, which
are due to the impact of RAI on non-thyroid tissue, are one of
the major causes of morbidity in thyroid cancer survivors (2, 3).
Salivary glands are one of the most affected tissues.
The sodium iodide symporter has also been shown to be
present in salivary tissue (1). Consequently, salivary glands have
the ability to specifically concentrate iodine (1, 4), although its
physiological role is not as yet elucidated. Salivary gland dys-
function after RAI treatment occurs quite frequently, even with
a first therapy or low-dose therapy (5, 6). Salivary gland damage
occurs in a dose-dependent manner but reported incidence rates
vary widely from 5 to 86% (2, 7–10). More damage also seems to
occurwith treatment protocols involvingwithdrawal from thyroid
hormone than with recombinant human thyrotropin (rhTSH)
protocols (5). The parotid glands appear to suffer damage more
frequently than the submandibular glands (4, 6, 10). Salivary gland
dysfunction can present as sialadenitis, xerostomia, taste alter-
ations, hypogeusia, sialolithiasis, dental caries, stomatitis, salivary
gland or oral infections, facial nerve damage, and even salivary
gland neoplasia (6, 9). Although side effects such as xerostomia
may be transient, they may also persist for longer periods, be
delayed in onset, or even be permanent (11, 12). Such events can
profoundly decrease patient quality of life (2, 3).
Radioactivity has been demonstrated in tears (13) and contact
lenses (14) after RAI administration, and the lacrimal system
is another organ system affected by RAI. Lacrimal dysfunction
can be manifest as epiphora, tearing, ocular dryness or xeroph-
thalmia, and recurrent or chronic conjunctivitis. Xerophthalmia
and abnormal lacrimal function tests were noted in 18 (9) and
92% (15) of patients, respectively after RAI therapy. Various rates
of lacrimal dysfunction have been reported in other studies. These
include conjunctivitis in 23% (16), significant tearing in 5% (17),
“watery eyes” in 10% (18), and various symptoms of lacrimal
dysfunction in 9.7% (19).
Nasal tissues are also affected by RAI. Nasopharyngeal tissues
do not express the sodium iodide symporter (20), in contrast to
the finding of its expression in extra-thyroidal tissues such the
salivary glands (20) and lacrimal system (21). However, iodine
may be transported non-specifically from the lacrimal system into
the nasal ducts, and then from the interstitial surface of nasal ducts
into the ductal lumen and out onto the nasal mucosal surface. A
recent retrospective study (19) showed that the nasal side effects
of RAI declared themselves within 1–2weeks of the therapeutic
dose. The mean time of onset of nasal symptoms was 11 days. The
rate of nasal dysfunction was 10.5%: similar to the occurrence rate
of 9.7% for lacrimal dysfunction. The nasal complaints included
nasal pain, nasal tenderness, bloody nasal discharge, and dry
nose. RAI dose and body mass index were significantly positively
and negatively correlated with sustaining nasal side effects. Being
prepared for treatment using awithdrawal protocol was associated
with increased risk of nasal side effects.
This study was designed to prospectively study symptoms of
salivary dysfunction after RAI therapy, along with simultaneously
documenting objective measures of salivary gland functioning.
Nasal symptoms were concurrently assessed.
Materials and Methods
This was an observational, prospective, non-randomized study.
The aim of this study was to determine whether there was a
correlation between salivary symptoms and salivary functioning
as assessed by salivary scan parameters. The study was approved
by the Georgetown University Institutional Review Board.
Patients who were scheduled to undergo RAI treatment with I-
131 for differentiated thyroid cancer were recruited for the study.
Details of their thyroid cancer features, including thyroid cancer
stage as defined using the National Thyroid Cancer Treatment
Cooperative Study Group staging system (22, 23) were docu-
mented. Participation involved completion of two questionnaires
about salivary and nasal symptoms respectively and undergoing a
salivary gland scan using technetium-99m (99mTc) pertechnetate
performed prior to receiving RAI and 3months and 12months
after RAI treatment. Participation thus involved completion of
two questionnaires and a salivary scan on three separate occasions.
The salivary gland questionnaire included 15 questions and is
shown in Table 1. The nasal symptoms questionnaire included 16
questions and is shown in Table 2. Question number 12 on the
nasal questionnaire asked about a dry mouth, as did question 1
on the salivary gland questionnaire. Question 12 from the nasal
questionnaire was not included in the questionnaire score, but was
used to help determine whether patients answered the questions
consistently. Each positive response from the two questionnaires
was assigned one point, thus the score for each questionnaire
could potentially range from 0 to 15.
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TABLE 1 | Salivary gland symptoms questionnaire.
PLEASE RESPOND TO THESE QUESTIONS BY CHECKING THE
APPROPRIATE BOX
HAVE YOU EXPERIENCED THE FOLLOWING IN THE YES NO
LAST 3MONTHS?
1. Dry mouth
2. Altered taste
3. Lack of taste
4. Metallic or bitter taste
5. Difficulty in swallowing dry foods (e.g., bread, crackers)
6. Difficulty speaking
7. Pain in the salivary glands in front of the ear
8. Pain in the salivary glands under the jaw
9. Painful mouth or ulcers in the mouth
10. Pain with swallowing
11. Swelling in the salivary glands in front of the ear
12. Swelling in the salivary glands under the jaw
PLEASE ANSWER YES OR NO TO THE FOLLOWING YES NO
QUESTIONS
13. Have you had cavities filled by your dentist in the last
3months?
14. Have you needed to carry bottled water or drinks with you in
the last 3months?
15. During the last 3months have you routinely chewed gum or
sucked candies?
TABLE 2 | Nasal symptoms questionnaire.
PLEASE RESPOND TO THESE QUESTIONS BY CHECKING THE
APPROPRIATE BOX
HAVE YOU EXPERIENCED THE FOLLOWING IN THE YES NO
LAST 3MONTHS?
1. Feeling of generalized nasal discomfort
2. Feeling of a dry nose
3. Feeling that your nose is irritated
4. Feeling of a hot or burning nose
5. Feeling that the skin inside your nose is cracking
6. Crusting in the nose
7. Pain in the nose
8. Noticed blood on tissue paper
9. Experienced nose bleeds
10. Noticed an altered sense of smell
11. Been bothered by dry eyes
12. Been bothered by a dry mouth
PLEASE ANSWER YES OR NO TO THE FOLLOWING YES NO
QUESTIONS
13. Have you used saline nasal sprays in the last 3months?
14. Have you used any kind of ointments in your nose?
15. Have you needed to use a vaporizer or humidifier in your
home in the last 3months?
16. Have you used any kind of nasal rinses during the last
3months?
Salivary gland function was assessed using salivary gland
scintigraphy. Scintigraphy was performed following intravenous
injection of 8mCi (296MBq) of 99mTc-pertechnetate. Following
isotope administration, the patient was placed supine with the
head slightly extended. A support was placed behind the patient’s
neck and to the sides of the head to minimize head motion. Cam-
era settings included a 128 128 matrix with a 2.67 zoom, energy
window at the 140KeV 99mTc photopeak with 15% symmetric
window. A high-resolution parallel hole collimator was used.
TABLE 3 | Characteristics of study participants (number=15).
Characteristic (continuous variables) Mean (SD) Median (Q1–Q3)
Age (years) 45.7 (14.9) 42.0 (33.0–55.0)
Weight 81.5 (15.8) 76.0 (69.0–86.0)
BMI 28.3 (5.4) 26.8 (24.2–32.9)
Characteristic (categorical variables) Number Percentage
Sex Female 11 73
Male 4 27
Menopausal status Pre-menopausal 6 40
Post-menopausal 5 33
n/a 4 27
Co-existent Hashimoto’s No 11 73
Yes 4 27
Sequential parotid and sublingual gland images were acquired
every 20 s for 20min. Two milliliters of a 100% lemon juice
solution were then administered with a syringe and images were
acquired at the same frame rate for a further 20min. Regions of
interest were drawn for the parotid and submandibular glands.
Regions of interests for themouth and the respective backgrounds
(temporal area for parotid gland and submental area for sub-
mandibular gland) were also obtained. Background-corrected
time activity curves were then derived. Parotid and sublingual
gland functioning were assessed in the same study. The general
pattern of radiotracer changes during salivary scanning was as fol-
lows. Immediately after radiotracer administration, tracer accu-
mulation in the major salivary glands was observed, with more
accumulation in the parotid than in the submandibular glands.
After lemon juice administration, rapid secretion of activity from
all salivary glands was observed, with nadir levels reached within
3–4min from the start of stimulation. This washout of activity was
greater in the parotid than in the submandibular glands.
Two parameters were calculated: accumulation (uptake)
of 99mTc-petechnatate and secretion (excretion) of 99mTc-
petechnatate. Accumulation was defined as the ratio of gland to
background counts at the point of maximum counts. Secretion
was defined as the ratio of gland to background counts at the
nadir achieved after lemon juice stimulation subtracted from the
ratio of gland to background counts at the point of maximum
counts. The methodology used was similar to that described by
Aung and colleagues (24). Accumulation and secretion of both
the right and left salivary glands were obtained prior to RAI
treatment as a baseline for each individual patient. The baseline
values were compared with those obtained at the two time points
after RAI treatment. These time points after RAI therapy were
3months and 12months. The 3-month background-corrected
uptake ratio and the 12-month background-corrected uptake
ratio were each subtracted from the background-corrected uptake
ratio at baseline in order to generate the change that occurred
following RAI therapy.
During the study period, the isotope used for diagnostic RAI
scanning was I-123, with I-131 used for therapy. None of the con-
ditions surrounding the patient’s RAI therapy were manipulated
because of study participation. Patients received the RAI activity
and used themethod of TSH elevation prescribed by their treating
physician. In addition, recommendations in place regarding the
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use of salivary stimulants and hydration were those given by the
prescribing physician and/or nuclear medicine physician. During
the period of the study, patients were routinely admitted to an
isolation room in the hospital for 22 h after receiving their RAI
therapy. Patients were permitted to drink fluids, use sialogogues,
and eat 2 h after RAI administration. As part of the protocol,
use of lemon candy, use of fluids, and urination frequency were
carefully documented. With respect to lemon candy, the type of
lemon candy, amount, frequency, and duration of its use was
documented. Similarly for fluid intake, the type of fluid consumed,
and the amount, frequency, and duration of its use, was docu-
mented. Patients were also asked to quantify the length of time
for which they consumed more than their usual volume of fluids.
For urine output, the frequency of voiding during the initial 22 h
after RAI treatment was recorded.
The baseline characteristics of study population were calcu-
lated. Due to the very small sample size (n= 15), the assumption
of normal distribution could not be assessed. Non-parametric
tests without assumption of distribution were used for the anal-
ysis. The Spearman correlation coefficient was used to assess the
correlation among symptom score, scan results, and continuous
patient variables. The Wilcoxon rank sum test or Kruskal–Wallis
test was used to compare the distribution of symptom score and
scan results between the categories of patient variables.
Results
Patients were treated with RAI and underwent salivary scanning
during the period February 2009 to June 2010. Fifteen partici-
pants were consented for the study. All 15 patients completed the
baseline and 3-month symptom questionnaire and salivary scan.
Funding was only sufficient for eight patients to complete the 12-
month scan. The same eight patients also completed the symptom
questionnaires at 12months. The question used to assess the
reliability of response to the questions was consistently answered
in all cases. The characteristics of the participants are displayed
TABLE 4 | Parameters related to differentiated thyroid cancer and radioiodine treatment.
A. THYROID CANCER-RELATED PARAMETERS
Characteristic Number Percentage
Type of DTC PTC 11 73:3
fvPTC 3 20
FTC 1 6:7
Multifocal Yes 9 60
No 6 40
Cervical node involvement Yes 7 46:7
No 8 53:3
Vascular or capsular invasion Yes 4 26:7
No 11 73:3
Extra-thyroidal extension Yes 3 20
No 12 80
Distant metastases Yes 1 6:7
No 14 93:3
DTC stage I 6 40
II 6 40
III 3 20
B. RADIOIODINE-RELATED PARAMETERS
Characteristic (continuous variables) Mean (SD) Median (range)
Radioiodine activity (mCi of I-131) [mBq] 126 (29) [4.6 (1.1)] 106 (100–182) [3.9 (3.7–6.7)]
TSH value (mIU/L) 113 (41) 98 (40–205)
Length of time that lemon candies were used (in subset using candies) (hours) 27 (24) 22 (8–94)
Number of lemon candies per hour during first 22 h (in subset using candies) 2.3 (1.1) 2 (1–4)
Length of time participants tried to increase hydration (hours) 36.9 (27.6) 22 (12–120)
Volume of fluid per hour during first 22 h (fluid ounces) [mL] 10.6 (3.2) [313.5 (94.6)] 10 (4–16) [295.7 (118.3–473.2)]
Number of urinations while awake during first 22 h 7.5 (2.3) 8 (3–12)
Number of times awoke from sleep to urinate during first 22 h 3.3 (1.8) 3 (1–8)
Characteristic (categorical variables) Number Percentage
Method of TSH elevation
rTSH 12 80
Withdrawal 3 20
Use of lemon candy
Yes 11 73
No 4 27
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in Table 3. The mean age of the patients was 45.7 years and
73% of them were female. The relevant details about the patient
thyroid cancer characteristics are shown in Table 4A. The major-
ity of patients had papillary thyroid cancer of typical histology.
Approximately, 50% hadmultifocal disease and/or cervical lymph
node involvement. One patient had distant metastases.
Twelve out of 15 patients were prepared for RAI administra-
tion using a recombinant rhTSH protocol. Details regarding RAI
administration and attendant use of sialogogues and fluids are
shown in Table 4B. Mean and median TSH values for all 15
patients were 113 and 98mIU/L, respectively. Mean and median
RAI activities administered were 126mCi (4.6GBq) and 106mCi
(3.9GBq), respectively. Patients attempted to drink more than
their usual volume of fluids for amean of 36.9 h. Themean volume
of fluid consumed during the initial 22 h of participant hospital-
ization was 10.6 fluid ounces (313.6mL) per hour. Fluids con-
sumed included water, orange juice, apple juice, lemon juice, and
Gatorade®. Eleven out of 15 patients used sour candies following
RAI administration. Those that used lemon candies used a mean
of 2.3 candies per hour during the initial 22 h. The mean length of
lemon candy use was 27 h. The lemon candies used included the
following: Lemonheads, Brachs, Jolly Ranchers, Sour Beans, Cit-
ron, sour gummies (various brands), Sour Patch, and Warheads.
During their inpatient stay, participants urinated a mean of 7.5
times during waking hours and 3.3 times during the night.
The number of salivary and nasal symptoms reported by
patients at baseline, 3months, and 12months are shown in
Figure 1. Themean increases in the number of symptoms at 3 and
12months over baseline are shown in Table 5A. The mean num-
ber of salivary, nasal, and total symptoms at 3months increased
significantly over the number of symptoms at baseline by 3.7, 2.7,
and 6.3 symptoms, respectively (p values 0.001, 0.0046, <0.001).
The mean increases in the number of salivary, nasal, and total
symptoms at 12months were non-significant at 1.3, 1.3, and 2.5
symptoms, respectively.
The general pattern of radiotracer changes during salivary
scanning was described in the Section “Materials and Methods.”
A representative example of salivary gland accumulation and
secretion is shown in Figure 2. Themean parotid gland accumula-
tion and secretion of radioisotope generally declined at 3months,
compared with baseline. The declines in right parotid accumu-
lation and secretion at 3months were significant (see Table 6A;
Figure 3). The changes in left parotid accumulation and secre-
tion at 3months, however, were not significant (see Table 6A;
Figure 4). None of the changes in submandibular functioning
or parotid gland functioning at 12months, were significant (see
Table 6A.) All the changes in salivary function were charac-
terized by great variability, as can be seen in Table 6A and
Figures 3 and 4.
There was no association between the increase in salivary,
nasal, or total symptoms and the change in scintigraphy mea-
sures. However, the increases in nasal and total symptoms were
significantly greater in those with co-existent Hashimoto’s disease,
compared with those without this condition (p values 0.01 and
0.04, respectively) (seeTable 5B). The increase in nasal symptoms
was of lesser magnitude (p value 0.04), and the increase in total
symptoms trended to be less (p value 0.08), in those who used
sour candies, compared with those who did not. Body mass index
was significantly associated with increasing nasal symptoms at
3months (p values 0.05). Increased nasal symptoms at 3months
were positively associated with duration of increased hydration
(p value 0.01) (see Table 5B). With respect to the categorical
variables that were associated with greater decrement in sali-
vary parameters, these included increased body weight (p value
0.05), lower thyroid cancer stage (p value 0.05), pre-menopausal
status (p value 0.03), and absence of Hashimoto’s disease (p
value 0.05) (see Table 6B). The only continuous variable with a
significant association was fewer lemon candies per hour being
associated a greater decrement in parotid gland accumulation at
3months (p value 0.03). In this small study, neither symptoms nor
Baseline 3 months 12 months Baseline 3 months 12 months
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FIGURE 1 | Symptoms.
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TABLE 5 | Symptoms developing after radioiodine treatment and associated variables.
A. INCREASE IN SYMPTOMS OVER BASELINE
Type of symptoms Mean (SD) p Value Median (Q1–Q3) Range
Salivary
Increase over baseline at 3months 3.7 (2.7) 0.001 3.0 (1.0–7.0) 0–8
Increase over baseline at 12months 1.3 (2.1) NS (0.12) 0.0 (0.0–2.5) 0–5
Nasal
Increase over baseline at 3months 2.7 (3.1) 0.0046 2.0 (0.0–3.0) 0–11
Increase over baseline at 12months 1.3 (1.6) NS (0.06) 0.5 (0.0–2.5) 0–4
Total
Increase over baseline at 3months 6.3 (4.3) <0.001 6.0 (3.0–10.0) 0–14
Increase over baseline at 12months 2.5 (3.5) NS (0.06) 1.0 (0.0–5.0) 0–8
B. VARIABLES ASSOCIATED WITH INCREASE IN SYMPTOMS OVER BASELINE
Type of symptoms Categorical variables (yes vs. no) Symptoms in patients with variable vs. without
Mean (SD)
p Value
Increase in nasal symptoms at 3months Co-existent Hashimoto’s 63.8 vs. 1.51.6 0.01
Use of lemon candy 1.51.7 vs. 5.84.1 0.04
Increase in total symptoms at 3months Co-existent Hashimoto’s 103.4 vs. 53.9 0.04
Use of lemon candy 5.13.9 vs. 9.83.8 0.08
Type of symptoms Continuous variables Spearman correlation p Value
Increase in nasal symptoms at 3months BMI 0.665 0.05
Increase in nasal symptoms at 3months Duration of increased hydration 0.767 0.01
FIGURE 2 | Salivary scintigraphy. Upper figure shows regions of interest,
lower figure shows time activity curves (y axis= counts per second, x
axis=minutes, lemon juice was administered at the 20min time point).
Red= right parotid, green= left parotid, yellow= right submandibular gland,
pink= left submandibular gland, blue=parotid background,
turquoise= submandibular background, brown=mouth.
scintigraphy measures appeared to be affected by the method of
TSH elevation or the RAI dose administered.
Discussion
This study showed an increase in symptoms of salivary gland dys-
function 3months followingRAI treatment followed by a decrease
in symptoms by 12months. At the same time, there was a decline
in scintigraphy parameters that reflect parotid salivary gland func-
tioning. Both accumulation and secretion of radiotracer were
affected, with the right parotid being more affected than the
left parotid. However, surprisingly, there was lack of correlation
between salivary symptoms and scintigraphy measures of salivary
function.
This is in contrast to a recent study in which all eight patients
who had oral symptoms consistent with salivary dysfunction
12months after RAI therapy were reported to have their salivary
dysfunction confirmed by salivary scintigraphy (25). However,
the particular deficit noted on scintigraphy (parotid vs. sub-
mandibular gland, accumulation vs. secretion) was not reported.
However, another study also did not show correlation between
symptoms and objectivemeasures of salivary function (26). In this
study of patients who received or did not receive RAI therapy,
salivary scintigraphy parameters or salivary flow measured by
sialometry were not associated with xerostomia or dysphagia (26).
However, dysphagia and reduced parotid secretion were each
associated with RAI therapy. An additional study examining cor-
relation of symptoms with objective measures of salivary function
in patients with thyroid cancer found that xerostomia was cor-
related with the number of salivary glands showing worsening
scintigraphy parameters and that xerostomia correlated better
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TABLE 6 | Changes in salivary scintigraphy after radioiodine treatment.
A. CHANGE IN SALIVARY PARAMETER
Salivary gland parameter
(expressed as uptake ratio)
Change at 3months
compared with 0months
Change at 12months
compared with 0months
Mean SD p Value Mean SD p Value
Salivary accumulation
R. parotid 2.16 2.58 0.006 1.69 2.50 0.09
R. submandibular  0.76 2.03 NS  0.91 2.67 NS
L. parotid 1.32 3.31 0.15 1.03 2.19 0.23
L. submandibular  0.27 2.43 NS  0.57 1.55 NS
Salivary secretion
R. parotid 1.69 2.54 0.022 1.03 2.23 0.23
R. submandibular  0.78 2.03 NS  0.96 2.61 NS
L. parotid 0.92 3.23 0.28 0.29 1.85 0.67
L. submandibular  0.28 2.34 NS  0.58 1.50 NS
B. VARIABLES ASSOCIATED WITH CHANGE IN SALIVARY PARAMETERS AT 3MONTHS COMPARED WITH 0MONTH
Salivary gland parameter (expressed as uptake ratio) Categorical variables Change in parameter with vs. without p Value
R. parotid accumulation Weight 76 vs. >76 kg 0.928 vs. 3.51.5 0.05
Stage TCR I vs. II vs. III 3.42.1 vs. 2.32.5 vs.  0.62.1 0.06
R. parotid secretion Weight 76 vs. >76 kg 0.52.8 vs. 3.01.5 0.07
Stage TCR I vs. II vs. III 3.12.3 vs. 1.62.1 vs.  1.01.8 0.06
L. parotid accumulation F preM vs. postM 2.93.1 vs.  1.23.0 0.03
Co-existent Hashimoto’s (yes vs. no)  1.63.4 vs. 2.42.7 0.05
Stage TCR I vs. II vs. III 3.12.8 vs. 1.13.5 vs.  1.81.2 0.05
L. parotid secretion F preM vs. postM 2.63.0 vs.  1.42.9 0.03
Co-existent Hashimoto’s (yes vs. no)  1.73.3 vs. 1.92.8 0.05
Stage TCR I vs. II vs. III 2.72.9 vs. 0.43.4 vs.  1.71.4 0.05
Salivary gland parameter (expressed as uptake ratio) Continuous variables Spearman correlation p Value
R. parotid accumulation No of lemon candies/hour  0.69 0.03
R. parotid secretion Times urination day  0.63 0.06
L. parotid accumulation Volume/hour  0.61 0.08
Times urination day  0.58 0.09
L. parotid secretion Volume/hour  0.64 0.06
with scintigraphic measures of submandibular dysfunction than
parotid dysfunction (27).
The failure of symptoms of salivary function to correlate with
salivary parameters in this study is most likely due to under-
powering of the study. However, given that similar lack of cor-
relation has been reported in other studies too (26, 27), per-
haps additional factors contributing to symptomatology need to
be investigated. The lack of correlation between symptoms and
function may also be due to failure to collect data about other
more pertinent symptoms that perhaps better mirror functioning.
If true, this highlights the need for better, validated symptom
questionnaires.
Variables associated with either salivary symptoms or scintig-
raphy changes have been elucidated. Higher activities of RAI
have been associated with a greater frequency of xerostomia
and greater changes in scintigraphy parameters (27). Another
study identified patient age as being associated with decreased
parotid accumulation and decreased salivary flow, whereas having
received RAI therapy was associated with decreased parotid
secretion and decreased salivary flow (27). In this study, the
variables that were associated with increased salivary symptoms
were different, and even of opposite impact, than the variables
associated with a decline in salivary scan parameters. By way
of illustration, co-existent Hashimoto’s thyroiditis was associated
with an increase in symptoms at 3months but a lesser decline
in parotid parameters at 3months. It is possible that the lesser
decline in salivary function in patients with Hashimoto’s occurred
because some dysfunction already existed prior to RAI due to
underlying autoimmunity. In this present study, use of lemon
candy, which has been shown in another study by Kulkarni
and coworkers to decrease the radiation dose absorbed by the
salivary glands (28), was associated with less nasal symptoms
and less total symptoms. A greater number of lemon candies
used per hour was also associated with less decrement in right
parotid accumulation at 3months in the present study. BMI
and weight were positively associated with number of symptoms
and greater decrement in salivary parameters; advancing thy-
roid cancer stage was associated with lesser decline in salivary
parameters. If confirmed, these findings could be associated with
altered handling of iodine associated with body composition,
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FIGURE 4 | Left parotid.
and the proportion of RAI taken up by non-thyroid tissue vs.
residual thyroid cancer.
In confirmation of other studies, we show that there is a lesser
effect of RAI therapy on submandibular functioning (4, 6, 10).
The greater impact of ionizing radiation on the parotid glands
is thought to due to their greater activity and greater content
of serous cells, compared with the mixed serous and mucinous
cell content of the submandibular glands (6). We are not aware
of prior studies that suggest a greater effect of RAI therapy on
the right parotid, as opposed to the left. Most studies report
combined bilateral salivary gland parameters, but one prior study
that reported separate function for right and left glands did not
report any differential effect (27).
This study also gives new information about the duration of
nasal symptoms after radioiodine therapy. A prior retrospective
study has shown a mean time of onset of nasal symptoms of
11 days and no documentation of continuing symptoms from
chart review of 3-month and 12-month endocrinology follow-
up visits (19). This study, however, shows that, as demonstrated
by questionnaire completion during a prospective study, nasal
symptoms were still clearly present at 3months.
The limitations of this study include the very small sample
size, a non-validated questionnaire, lack of a control group not
treated with RAI, and lack of randomization. To illustrate the
need for a control group who did not receive RAI, some salivary
scintigraphic parameters were more robust at 3months than at
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baseline; a control group would have given insight as to whether
this reflected a natural variation in salivary function and/or in the
measurement techniques used. However, a positive aspect of the
study is that the data were collected prospectively.
There is a clear need for better understanding of the cause of
symptoms of salivary dysfunction after RAI administration. If
these symptoms are confirmed in additional larger studies not
to correlate well with objective measures of salivary functioning,
then an investigation of potential alternative causes of these symp-
toms is needed. In addition, risk factors for both symptoms and
altered scintigraphy parameters need to be better documented,
especially given the opposing effects of some of these risk factors
documented here.
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